RESULTS ARE IN.
Long-term overall survival data from participants in the CENTAUR ALS trial have been published in Muscle & Nerve.
The Power of Connected Action
Honored to be recognized by Fierce Biotech as one of the most promising private biotechnology companies of 2020.
THE RESULTS ARE IN.
The CENTAUR ALS trial data have been published in the New England Journal of Medicine.
An unconventional approach redefines what’s possible.
To go far, we must go together. By collaborating with patients, families, physicians and partners, we’re working towards our destination by developing a drug that prevents nerve cell degeneration. Driven by innovation and relentless curiosity, our connections propel us forward in pursuit of what’s next.
In Pursuit of
Every Moment.
Together, with our growing leadership team of industry veterans, physicians and scientists, we seek new perspectives from research, from each other, and most importantly, from patients and their families. We know the answer is out there. And every day brings us closer to reaching it.
Careers
We believe in the power of the individual, the strength of personal connection, and the passion of humanity to address the effects caused by neurodegenerative diseases. Amylyx was built on the foundation of audacious curiosity, relentless drive, and meaningful relationships. If that sounds like you, we’d love to talk.
Clinical Trials
Awards
Business Insider 2020 30 Leaders Under 40 Changing Healthcare
Fierce Biotech's 2020 Fierce 15
Xconomy Young Innovator 2019
PM360 Elite 2020 Drug Researchers and Developers